1	Transient loss and recovery of oral chemesthesis, taste and smell with
2	COVID-19: a small case-control series
3	
4	by
5	Elisabeth M. Weir ^{1,2} , Cara Exten ³ , Richard C. Gerkin ⁴ , Steven D. Munger ^{5,6,7} ,
6	and John E. Hayes 1,2*
7	
8	¹ Sensory Evaluation Center,
9	² Department of Food Science, College of Agricultural Sciences,
10	The Pennsylvania State University, University Park PA 16802
11	
12	³ Ross and Carol Nese College of Nursing, the Pennsylvania State University, University Park PA
13	16802
14	
15	⁴ School of Life Sciences, Arizona State University, Tempe AZ 85287
16	
17	⁵ Department of Pharmacology and Therapeutics, University of Florida College of Medicine,
18	Gainesville FL, 32610,
19	⁶ Center for Smell and Taste, University of Florida, Gainesville FL, 32610
20	7 Department of Otolaryngology, University of Florida College of Medicine, Gainesville FL,
21	32610
22	*Corresponding Author:
23 24 25 26	Dr. John E. Hayes; Email: <u>jeh40@psu.edu;</u> Twitter: @TasteProf
27	Key Words: gustation; anosmia; trigeminal; recovery; longitudinal; olfaction

28 Abstract

29 Anosmia is common with respiratory virus infections, but loss of taste or chemesthesis is rare. Reports of true taste loss with COVID-19 were viewed skeptically 30 until confirmed by multiple studies. Nasal menthol thresholds are elevated in some with 31 prior COVID-19 infections, but data on oral chemesthesis are lacking. Many patients 32 recover quickly, but precise timing and synchrony of recovery are unclear. Here, we 33 collected broad sensory measures over 28 days, recruiting adults (18-45 years) who were 34 COVID-19 positive or recently exposed (close contacts per U.S. CDC criteria at the time 35 of the study) in the first half of 2021. Participants received nose clips, red commercial 36 jellybeans (Sour Cherry and Cinnamon), and scratch-n-sniff cards (ScentCheckPro). 37 Among COVID-19 cases who entered the study on or before Day 10 of infection, 38 Gaussian Process Regression showed odor identification and odor intensity (two distinct 39 measures of function) each declined relative to controls (close contacts who never 40 developed COVID-19), but effects were larger for intensity than identification. To assess 41 changes during early onset, we identified four COVID-19 cases who enrolled on or prior 42 to Day 1 of their illness - this allowed for visualization of baseline ratings, loss, and 43 recovery of function over time. Four controls were matched for age, gender, and race. 44 Variables included sourness and sweetness (Sour Cherry jellybeans), oral burn 45 (Cinnamon jellybeans), mean orthonasal intensity of four odors (ScentCheckPro), and 46 perceived nasal blockage. Data were plotted over 28 days, creating panel plots for the 47 eight cases and controls. Controls exhibited stable ratings over time. By contrast, 48 49 COVID-19 cases showed sharp deviations over time. No single pattern of taste loss or 50 recovery was apparent, implying different taste qualities might recover at different rates. 51 Oral burn was transiently reduced for some before recovering quickly, suggesting acute loss may be missed in data collected after acute illness ends. Changes in odor intensity 52 or odor identification were not explained by nasal blockage. Collectively, intensive daily 53 testing shows orthonasal smell, oral chemesthesis and taste were each altered by acute 54 COVID-19 infection, and this disruption was dyssynchronous for different modalities, 55 with variable loss and recovery rates across modalities and individuals. 56

58 1. Introduction

59 The COVID-19 pandemic caused by the SARS-CoV-2 virus is one of the most devastating infectious disease outbreaks since the H1N1 avian flu of 1918 [1, 2]. By the 60 end of 2021, roughly two years after the start of the pandemic, there were over 281 61 million cases of COVID-19 globally, resulting in over 5.4 million deaths [3]. Early in the 62 pandemic, SARS-CoV-2 infection was associated with myriad symptoms, one of the 63 most common being anosmia [4-7]. Meta-analyses of dozens of early studies suggested 64 half to three-quarters of COVID-19 patients lost their sense of smell [8]. Further, smell 65 66 loss was the most predictive symptom of COVID-19 [9] in the first several waves.

In contrast to other respiratory illnesses that cause acute anosmia – including 67 those caused by rhinoviruses, influenza viruses, and common coronaviruses - both taste 68 and chemesthesis function were reportedly lost in some people with COVID-19 [10-12]. 69 Taste loss in the absence of smell loss is rare [13], and many individuals may mistakenly 70 conflate the impaired flavor perception associated with anosmia with a true loss of taste 71 72 function. However, one large crowd-sourced study reported ~60% of COVID-19-positive individuals had impaired perception of specific taste qualities (i.e., sweet, salty, sour or 73 74 bitter tastes), suggesting taste loss in these individuals is distinct from impaired flavor perception accompanying smell loss [10, 14]. The findings of that study and others 75 based on self-reports (e.g., [15-17]), were confirmed by psychophysical tests of taste 76 function, suggesting ~47 to 64% of COVID-19 positive individuals experience taste loss 77 [18, 19]. As a result, taste dysfunction (distinct from impaired flavor perception due to 78 79 smell loss) is now also recognized as a common symptom of COVID-19 [20, 21]. 80

Data on disruption of chemesthesis associated with COVID-19 remains quite limited. Consistent with many patient anecdotes that chili and ethanol burn were 81 transiently depressed (e.g., [22]), studies relying on self-report suggested roughly half of 82 individuals with COVID-19 experienced disruptions of chemesthesis [10]. In a small 83 study of Italians with COVID-19-associated smell loss, 57% of patients had reported a 84 severe impairment of nasal chemesthesis at initial diagnosis, but over 90% reported full 85 recovery of chemesthesis six months later [23]. A Swedish study that used "olfactory" 86 stimuli known to concomitantly activate the trigeminal system (e.g., vinegar, chopped 87 garlic, vodka) provided evidence for impairment of nasal chemesthesis [24]. Thus, while 88 self-report and clinical assessment both suggest COVID-19 may associate with acute 89

impairment of chemesthesis in many individuals, the time course of loss and recovery is
lacking, as is any assessment of the impact on oral chemesthesis. We attempt to fill
these knowledge gaps here.

In approximately 85% of COVID-19 cases where chemosensation (smell, taste 93 and/or chemesthesis) has been affected, recovery of chemosensory function is typically 94 seen within ~6 weeks [6, 25, 26]. Unfortunately, some patients do not report 95 appreciable recovery after many months [13, 26-30]. However, without daily 96 chemosensory testing, the precise timing of recovery remains unknown [6, 25, 31]. 97 Because patient anecdotes suggest the timing of recovery of different chemical senses 98 99 may be dyssynchronous [26], we assessed smell, taste, and chemesthesis function acutely and transiently over 28 days by collecting longitudinal data using commercially 100 101 available chemosensory stimuli in a cohort of patients diagnosed with COVID-19 and control participants without COVID-19 in early 2021. Here, we present a small case-102 103 control series using temporally intensive data collection from remote daily testing. We focus on a handful of COVID-19 cases that allow for visualization of loss and recovery of 104 chemosensory function as well as baseline ratings obtained prior to the onset of illness. 105

106 **2. Methods**

107 2.1 Study design and recruitment

This prospective study investigated COVID-19-related chemosensory dysfunction 108 109 in a community-derived sample of 18- to 45-year-old adults recruited on and around the campus of a large public university in rural central Pennsylvania (i.e., the area 110 surrounding State College, PA). Enrollment began in February, 2021, on a rolling basis 111 using geotargeted ads on social media, and ended in May, 2021. Potentially interested 112 individuals were asked to contact a study team member (author EMW) via email if they 113 believed they were qualified for the study, who then emailed them a link to a brief 114 115 screening questionnaire. The screening questionnaire asked questions about demographics, prior diagnosis of COVID-19, contact with a COVID-19-positive (COVID-116 19+) individual, and any recent symptoms of COVID-19. Contact with a COVID-19+ 117 118 individual was defined by the Centers for Disease Control (CDC) screening criteria in use at the time of enrollment (specifically, 15 or more minutes within 6 feet of a 119 120 confirmed case of COVID-19). Due to the fluidity of the COVID-19 pandemic in early

121 2021, however, a strict timeline was not rigidly enforced and enrollment occurred on a

122 case-by-case basis. As vaccines were not available to non-health care workers at study

123 initiation in February, 2021, but became more widely available during the enrollment

124 window, we added a short retroactive questionnaire to the end of the study to gather

self-reported information on vaccination status and date. No attempt was made to

126 confirm these reports against medical records.

Participants with the following conditions were excluded: not diagnosed with 127 COVID-19 or not a close contact of a COVID-19+ individual, pregnant, food allergies (or 128 another reason they could not consume commercial jelly beans), prior history of a 129 disease of the central nervous system (including Alzheimer's disease, multiple sclerosis, 130 Parkinson's disease, Huntington's disease, brain tumor), nasal obstruction 131 (tumor/polyps), a history of nasal surgery, history of a severe head injury/concussion, 132 history of chronic sinus infections, history of radiation therapy to the head or neck 133 134 (ever), recent chemotherapy (within the last year), a prior diagnosis of smell or taste loss, diabetes, history of lung/pulmonary disease or neurological disease, were unwilling 135

136 to create a PayPal account for compensation if they did not already have one, or were

130 to create a rayr at account for compensation if they are not arready have of137 below 18 years or above 45 years of age.

Data were collected using REDCap, a secure data capture platform for clinical
research [32, 33] on a server hosted and maintained by the Penn State College of
Medicine in Hershey, PA. The study was performed in compliance with the principles of
the Declaration of Helsinki, informed consent was obtained electronically, and the
specific protocol was approved by the Institutional Review Board at Penn State
(STUDY00016377). The subject identification numbers referenced below were known
only to our research staff and were not known to the participants or other individuals.

145 2.2 Chemosensory stimuli and assessment

The longitudinal design consisted of brief daily assessment every day for 28 days,
followed by four additional follow-up sessions every 2 weeks, for a total of 32 sessions
over a 12-week period. This report focuses on data from the first 28 days of testing. In
each daily session, participants were asked to complete questions on COVID-19 status or
symptoms that had changed since the last session, as well as self-administered
psychophysical smell and taste tests. They were instructed to minimize any distracting

smells or odors before any sensory testing and were also asked not to eat or drink(anything other than water) or smoke for at least 30 minutes prior to testing.

Upon enrollment, the first author arranged contactless delivery of all research
materials in a large plastic zip-top bag. Specifically, participants were given 32
ScentCheckPro cards (Item #098515, Lot #0821) from Taylor Corp (North Mankato,
MN). Each ScentCheckPro card consisted of 4 microencapsulated scents in a scratch-nsniff format, with one scent located near each corner of the postcard sized card. The four
scents on a given card were some combination of the following: coconut, grape, coffee,
lemon, bubble gum, popcorn, pine, cinnamon, flowers, banana, or none of these.

161 Participants were also given 36 lidded plastic 2 oz souffle cups (Solo P200N; Lake Forest IL) labeled with blinding codes. Individual cups contained one of two kinds of red 162 colored jellybeans (Jelly Belly, Fairfield, CA): either Sour Cherry (Lot #20200601) or 163 Cinnamon (Lot #200731). Each cup contained three jellybeans of a single flavor. 164 165 Jellybeans are a highly familiar confection in the United States that are made with sweeteners (sugar, and/or corn syrup), corn starch, confectioners glaze, added color and 166 natural or artificial flavors. They have a shiny candy shell and a soft gel center, and come 167 168 in many different colors and flavors including fruit or spice flavors. With the nose pinched closed, the Sour Cherry jellybean used here evoke both sweetness and sourness, 169 while the Cinnamon jellybean elicits sweetness and a mild warming/burning sensation. 170 Because of the glazed outer shell, jellybeans have little to no orthonasal smell, and both 171 jellybeans had a similar red color, so there were no obvious cues of the specific flavor in 172 each cup. Across days, jellybean presentation order was counterbalanced with pairwise 173 174 randomization, so that a participant who was presented with Sour Cherry on Day 1 175 would get Cinnamon on Day 2, while the next participant would start with Cinnamon on 176 Day 1 before receiving Sour Cherry on Day 2. This procedure was used to maximize the range of chemosensory stimuli used in the study (i.e., taste, smell, and chemesthesis) 177 while minimizing participant burden on any given day of the study (i.e., a very brief test 178 time to enhance compliance). Individual lidded cups were labeled with random 3-digit 179 blinding codes, and these codes were programmed into REDCap prompts for each 180 session to help ensure participants sampled the correct jellybean on the correct day. We 181 also provided a disposable foam padded nose clip (A-M Systems; Sequim WA; Model 182

#166500, Lot #189615) to allow ratings of oral sensation to be collected with occluded
nostrils to minimize olfactory input.

185 Once a day, participants were asked to rate how blocked their nose was using a horizontal 0-100 visual analog scale (VAS) scale anchored with 'Not blocked at all' to 186 187 'Completely blocked'. Participants were then asked to scratch the spot containing the encapsulated odorant on each postcard sized smell card with a coin or fingernail for 5-10 188 seconds before sniffing; they were then asked to bring the card one inch from their nose 189 and sniff the odor. For each odor spot, participants were asked to first identify the odor 190 they smelled from four multiple choice options presented in REDCap before rating the 191 192 perceived intensity of the odor on a 0-100 VAS anchored with labels of 'None' to 'Very intense'. This process was repeated for the four different odorants on a given card. 193

194 Next, participants were asked to pinch their nose closed using the provided nose clip and put all three jellybeans from the cup into their mouth. With their nose *pinched* 195 196 *closed*, they were asked to chew the jellybeans slowly, and rate the perceived intensity of various qualities on five different horizontal 0-100 VAS scales labeled 'None' to 'Very 197 intense'. These qualities included: sourness, sweetness, warming/burning, cherry 198 199 flavor, and cinnamon flavor. Participants were then asked to unpinch their nose and exhale (while still chewing the jellybeans) and rate the same five intensity scales with 200 their nose unpinched (data not shown). All five scales were presented in both conditions 201 (nose closed / nose open) to minimize any "dumping" artifacts [34]. To decrease daily 202 test time and participant burden on days 1 through 28, participants assessed only one 203 jellybean flavor per day (either Sour Cherry or Cinnamon, counterbalanced as described 204 205 above). In four follow up sessions at weeks 6, 8, 10 and 12, a longer assessment was 206 deemed reasonable, so participants were presented with two cups of jellybeans, one with 207 each flavor. These data are not reported here.

208 2.3 Categorization of participants as COVID-19 cases versus controls

For the purposes of this study, a *COVID-19 contact* was defined as a participant
who had been exposed to a COVID-19+ individual (e.g., 15 or more minutes within 6 feet
of a confirmed case of COVID-19, per US CDC guidelines at the time), but never
developed any symptoms or received a positive diagnosis in subsequent testing.
Conversely, a *COVID-19 case* was defined as a participant who was either formally
diagnosed with COVID-19 *or* began having symptoms while enrolled in the study

215 following their recent exposure. By studying close contacts who later became cases while enrolled in our study, we were able to observe acute changes in chemosensation using 216 217 controlled stimuli from the earliest days of their infection. When COVID-19 symptoms started prior to the participant receiving a positive COVID-19 diagnosis via clinical 218 testing (typically a positive PCR test), an estimated day of infection (Day 0) was defined 219 as the first day of symptoms. When a positive test preceded COVID-19 symptoms, the 220 date of the positive test was used as *Day o of infection*. Data from controls were not 221 centered on the day of infection, as these participants enrolled at their discretion. For 222 these individuals, the *day of rating (Day 0*) is defined as the first day of their 223

224 participation in the study.

225 2.4 Data analysis

Between February and May of 2021 (i.e., in the months prior to the Delta and Omicron 226 waves in North America), a total of 55 participants were enrolled in the study. For this 227 analysis, 39 participants with confirmed COVID-19 infection were identified as COVID-228 19 cases (Figure 1). Of these 39, 15 participants were identified as having an active 229 230 COVID-19 infection and enrolled in the study prior to or during the first 10 days of infection. Of these 15 participants, four COVID-19 cases entered the study on or before 231 day 1 of their infection, allowing us to capture acute changes in their symptoms 232 throughout their entire infectious period, including early onset of symptoms. As shown 233 in Figure 1, three more cases enrolled on days 2-4 of infection, and nine enrolled on day 234 5-10 of their infection. An additional 24 participants who had enrolled were identified as 235 COVID-19 cases, but only after their initial 10-days of infection had passed. Because we 236 237 were not able to enroll these subjects early enough to capture potential changes in chemosensory function during acute illness, data from these subjects were not included 238 239 in the present analyses. We plan to analyze and publish these data elsewhere to better understand recovery over time, but the focus of the current report is initial loss during 240 241 early illness. Finally, in this analyses, 15 participants were identified as controls (i.e., they did not develop COVID-19 during the duration of the study). 242 243




Figure 1: Flow diagram summarizing selection of cases and controls for this case series. Blue boxes indicate the 30 participants included in the Gaussian Process model regression, and gray boxes indicate the 8 individuals shown in the in-depth panel plots.

- 245 Here, we wanted to assess whether deviation of smell intensity in the cases differed from
- controls, so we identified the fifteen COVID-19 cases in our study who had enrolled on
- or before day 10 of either infection and tested if their average deviation in smell
- 248 intensity over time differed from the 15 participants who were controls. To do this, a
- 249 grand mean of smell intensity was calculated for the controls across all days and
- 250 individuals. Deviation scores (deltas) for the 15 COVID-19 cases were then calculated by
- subtracting that individual's ratings from the grand mean of the 15 controls, resulting in
- a deviation score for smell intensity. Similarly, for the controls, we subtracted each
- 253 control's *individual* rating from the grand mean of all controls, to get a deviation score
- 254 for that rating relative to performance of the group. We used a Gaussian Process

255 Regression model to analyze the deviation (delta) scores for cases and controls over time (both individually and as a group). A Gaussian Process model is a probabilistic 256 257 unsupervised machine learning concept used for regressions in which the model makes predictions by utilizing prior knowledge about the smoothness of plausible time series 258 and provides uncertainty measures for such predictions [35]. COVID-19 cases were 259 normalized on Day o of infection and missing values were extrapolated via the Gaussian 260 Process Regression model. Controls were normalized on Day o of rating. To be 261 conservative and avoid overfitting sparse data, ratings of the two jellybean flavors were 262 not modeled via Gaussian Process Regressions, as the counterbalancing of flavors across 263 264 days meant only half as many data points were available for analysis. Analyses and data visualization were conducted using SAS software (Version 9.4), R using RStudio 265 266 software (Version 2021.09.0), Python software (Version 3.9.10), or DataGraph version 4.7.1 (Visual Data Tools, Inc; Arlington TX). 267

268 Elsewhere, it has been suggested smell and taste changes occur within the first four days of disease onset [36], and the median incubation period for symptom onset is 269 approximately five days [37]. We observed the same overall pattern within our data; as 270 271 reported below, it became clear the confidence interval of cases did not include zero in the first week of infection. Given the unique opportunity to explore acute and early 272 changes in chemosensation in a small number of participants who had been enrolled 273 prior to acute illness, we also performed an in-depth analysis of these individuals, in 274 hopes of better understanding the initial trajectory of changes in chemosensation. 275

276 2.4 Selection of participants for in-depth case control series

Here, we describe a very small case series restricted to four specific cases who 277 278 enrolled in the study prior to or on Day 1 of infection (Figure 1). Studying these four 279 participants in detail allowed us to capture changes in symptoms throughout their entire infectious period, including early onset of symptoms. More specifically, this prospective 280 281 approach maximizes the potential to capture baseline ratings, loss, and recovery of chemosensory function that would not be possible with patients recruited only after they 282 were ill. This is a distinct and unique feature of this case series, as most other studies 283 have assessed chemosensory function multiple days into a participant's isolation period, 284 which does not allow for visualization of initial loss [30, 38-43]. For the other 12 285

- participants who entered on or before Day 10 of infection (see Figure 1), we did notcapture their initial loss, so they are not included in this analysis.
- From the 15 *controls*, four were selected as *matched controls* for the four COVID-
- 19 *cases*, based on age, gender, and race (Figure 1). To be considered for matching with
- a specific COVID-19 case, potential candidates were required to (a) provide data on a
- 291 minimum of 80% of days, and (b) remain active for the full 28-day data collection
- 292 period (to avoid bias from dropout over time). If more than one potential candidate met
- the age, gender, and race criteria to be included in a matched pair, the control used here
- 294 was randomly selected. Matching was performed manually by an experienced
- epidemiologist (author CE). This process resulted in a final analysis of four *cases* and
- 296 four *matched controls* (Figure 1; Table 1).

 Table 1: Participant demographics from COVID-19 case-control series identifying cases and matched controls.

ID	Status	Race (Self-Identified)	Gender (Self-Identified)	Age Range	Estimated Day of Infection relative to Day 0 of the Study
35	Case	White/Caucasian	Female	18-23	-4
3	Control	White/Caucasian	Female	18-23	n/a
45	Case	White/Caucasian	Female	18-23	0
10	Control	White/Caucasian	Female	18-23	n/a
62	Case	White/Caucasian	Male	18-23	1
10	Control	White/Caucasian	Male	18-23	n/a
63	Case	White/Caucasian	Female	38-43	-14*
22	Control	White/Caucasian	Female	38-43	n/a

* Follow up via email revealed this participant was exposed twice. Based on symptoms, the first exposure resulted in enrollment as a close contact, but not infection. The participant only became ill following the second exposure.

For these four *cases* and their *matched controls*, we plotted six key variables related to smell, taste, and chemesthesis. Specific outcomes were selected *a priori* by two authors (EMW and JEH) as being the most salient and theoretically interesting variables. These were: perceived *nasal blockage*, mean orthonasal *smell intensity* of the four odorants on a given ScentCheckPro card, *sourness* and *sweetness* (from the Sour

Cherry jellybeans), and oral *burn* (from the Cinnamon jellybeans). Also, we included *daily number correct* on the odor identification task. These seven variables were then
plotted across all 28 days to create a series of panel plots for all eight individuals.

In summary, ratings were collected on 101 point VAS, and variables summarized here were: daily ratings of *nasal blockage*; a daily measure of orthonasal *smell intensity* derived from the mean of four scratch-n-sniff spots on a ScentCheckPro card for a given day; oral *burn* ratings collected every other day from a Cinnamon jellybean; and *sweetness* and *sourness* ratings collected every other day from a Sour Cherry jellybean.

310 3. Results and Discussion

311 3.1 Odor identification scores and ratings of orthonasal intensity from a

312 commercial scratch-n-sniff card

For controls, the grand mean correct on the daily odor identification (OdorID)
across the entire study period was 3.32 out of 4 possible (Figure 2, Supplemental
Figures 1, 2). There was some evidence of a learning effect, as controls got slightly better
at the task over time (see upward slope, Figure 2A and 2B). For OdorID, the delta score
for cases deviates from zero, with a maximal dip occurring around days 5 to 8 (Figure
2A and 2B). Conversely, this dip was not observed in the controls, indicating that the
drop in OdorID performance was limited to COVID-19 cases.

After performing the OdorID task for 4 days, the median number correct for 320 controls increased by ~0.5, and after 14 days (two weeks), the median number correct 321 for controls increased by ~0.7-0.8 above the grand mean; that is, there was nearly 322 perfect performance on a 4 item OdorID task. Based on odor intensity ratings (discussed 323 below), smell loss for cases appears to be maximal near Day 5 (see Figure 2C and 2D). 324 Accordingly, we would also expect OdorID performance to be lowest on Day 5. However, 325 326 this is just when the first increase due to the learning effect appears to occur (Figure 2A and 2B). If we assume cases (at least those who are not totally anosmic) show similar 327 328 ability to learn as the controls, this offsetting bump upward would minimize the 329 apparent dip in OdorID performance seen around Day 5. Thus, the COVID-19associated drop in identification performance may appear smaller than it actually is due 330 to a simultaneous offsetting increase in performance due to learning (or practice). 331 Evidence of such learning is also seen in Supplemental Figures 1 and 2. 332

333 Regarding suprathreshold odor intensity, the grand mean of perceived intensity ratings for controls across time was 59.47 on 0 to 100 VAS. The mean on Day 0 was used to 334 335 calculate daily deviation scores for cases and controls (Figure 2C and 2D). Data were centered using Day o means so the delta could be more easily compared across the data 336 set. For the cases (Figure 2C and 2D), the delta score of smell intensity clearly deviates 337 from zero, and this difference was maximal in the first week of infection, as noted above. 338 In sharp contrast, this pattern is not seen in the controls, with a score of zero falling 339 inside the interquartile range across the entire study period (Figure 2D). This indicates 340 there was a significant drop in smell intensity for cases but not controls for ratings of the 341 scratch-n-sniff spots on commercial ScentCheckPro cards. In contrast with the learning 342 seen for the OdorID data, we failed to observe any evidence of a learning effect for smell 343 344 intensity ratings. Collectively, these data suggest OdorID tasks may be less sensitive to acute changes in smell with COVID-19, relative to odor intensity ratings, at least in 345 346 repeated testing situations that encourage learning or practice effects.






Figure 2. Individual (left) and group level (right) Gaussian Process Regression models for 15 controls (red) and 15 COVID-19 cases (black) who entered the study on or before day 10 of their infection. For cases, Day of Rating is centered on estimated day of infection. Odor identification scores (top) and odor intensity ratings (bottom) are shown as deviation scores calculated from a grand mean of controls across time. **(A)** Individual odor identification data in a Gaussian Process Regression model of deviation scores from 15 COVID-19 cases (red) and 15 controls (black). **(B)** Group level odor identification data in a Gaussian Process Regression model for COVID-19 cases (red) and controls (black). **(C)** Individual deviation scores for smell intensity ratings for 15 COVID-19 cases (red) and 15 controls. **(D)** Group level smell intensity data in a Gaussian Process Regression model for 15 COVID-19 cases (red) and 15 controls (black). In panels B and D, the solid line represents the group median, and the shaded region shows the interquartile range. Panels A and C show maximal loss roughly around day. Panel B shows some evidence of a learning effect for the OdorID task in the controls; no evidence of learning is seen for controls in the intensity task shown in panel D.

349 **3.2 Demographics of participants in case control series**

Given the maximal deviation in smell early in acute illness, we chose to explore the
specific changes in multiple chemosensory modalities in the handful of cases who
enrolled *prior* to onset of acute illness in greater detail. Demographics of four COVID-19
cases and four matched controls are summarized in Table 1. The mean age of
participants with COVID-19 was 26 years of age (range 21-43) and the mean age of
matched controls was 25.5 years of age (range 22-38).

356

357 3.3 Controls

Throughout the course of the study, controls exhibited normal function for smell, 358 taste, and chemesthesis (Figure 3). Specifically, mean scores on odor identification, 359 orthonasal smell intensity ratings, and ratings of perceived nasal blockage were 360 relatively constant across days, although some participants were more variable than 361 362 others. A few patterns deserve comment. For example, with Subject 1 we see a clear learning effect for odor identification where they became better at the task over time 363 (Figure 3). Separately, controls may vary in perceived nasal blockage from day to day. 364 For example, with Subject 3, we see a slight decrease in orthonasal smell intensity and a 365 slight increase in nasal blockage in the last four days of testing (Figure 3). Such mild 366 transient hyposmia would be wholly consistent with conductive smell loss due to nasal 367 blockage typically seen with allergies or the common cold. Similarly, for taste, ratings of 368 sweetness and sourness remained relatively constant throughout the course of the study 369 370 for controls, although ratings were noisier for some participants than others. One rating for Subject 22 deserves comment: in the third week of testing, we observed a sharp drop 371 in sour taste intensity and sharp increase in burn intensity, but only for a single day 372 373 (Figure 3). While we cannot be sure, we suspect they simply picked the wrong cup from the bag of samples, as Sour Cherry jellybeans should not burn and should be sour. 374 375 Subject 22 may have misread the 3-digit blinding code, or our research team may have mislabeled the cup. Either way, this single datum does not alter their overall pattern. 376 377 Also, we note Subject 22 tends to give Cinnamon jellybeans a relatively high amount of oral burn relative to the other participants; we might speculate they eat spicy food 378 infrequently, as large variation in burn ratings due to dietary exposure is very common 379 (e.g., [44-47]). 380

In summary, daily data from these four *controls* suggest individuals without

382 COVID-19 are able to correctly identify the odors from the ScentCheckPro cards, and to

consistently rate the various attributes from the cards (orthonasal intensity) and the

jellybeans (taste, burn). While some minor variation is observed over time and across

385 participants, the ratings are generally stable over the study period, in sharp contrast to

the COVID-19+ cases (Figure 4).




Figure 3: OdorID scores, and intensity ratings from matched controls over time. These participants (Subjects 1, 3, 10, and 22) show generally consistent ratings across the study. To help illustrate uniformity across the observation period, solid (colored) lines were fit via LOESS regression and dotted lines (gray) were fit via linear regression. A vertical line on Day o highlights the start of the 28-day study. Open hexagons (1st row) are the number correct on a ScentCheckPro card, while open diamonds (2nd row) are the mean daily smell intensity ratings from the same card. Open circles (3rd row) reflect ratings of perceived nasal blockage. Red symbols (rows 4, 5, and 6) reflect specific quality ratings from Sour Cherry jellybeans collected with a pinched nose. Orange triangles (row 7) indicate burn ratings from Cinnamon jellybeans collected with a pinched nose.

388 **3.4 Cases**

All four cases converted from being close contacts to being COVID-19+ while 389 390 enrolled in the study, enabling visualization of changes in their responses over time (Figure 4). For brevity, we only highlight a few notable points here and a more detailed 391 account is provided in the supplemental materials. When smell loss was observed, it was 392 largely unrelated to nasal blockage, consistent with prior reports [4-7, 10] and the idea 393 that COVID-19-associated smell loss arises from ACE2 receptor-mediated disruption of 394 the olfactory epithelium, rather than the conductive losses typically seen with the 395 common cold. Regarding chemesthesis, the lack of burn from the Sour Cherry jellybeans 396 397 served as a negative control, suggesting participants were successful in discriminating between burn from a Cinnamon jellybean and a lack of burn from a Sour Cherry 398 399 jellybean. From this, we can assume changes in burn observed here for the Cinnamon jellybeans was not merely a failure to understand the task. 400

401 3.4.1 Subject 35

Symptoms for Subject 35 included cough, runny nose/congestion, sore throat, 402 and headache. Odor intensity ratings dropped through day 15 before recovering; her 403 404 OdorID scores showed a similar pattern, but her data were noisier given the learning effect noted previously. Her nasal blockage resolved around Day 8, but she still showed 405 impaired smell. Sourness ratings declined until ~Day 15 while sweetness declined until 406 ~Day 6, before each began to recover. This was not merely a taste/flavor semantic 407 408 confusion, as ratings were obtained while wearing nose clips. Her data also suggest sweet and sour taste are each transiently affected with an active COVID-19 infection, 409 410 and loss and recovery may be dyssynchronous (i.e., sweetness did not recover as swiftly 411 as sourness). Separately, she showed large changes in burn from Cinnamon jellybeans, suggesting oral chemesthesis is affected by COVID-19 infection, and this may be 412 dyssynchronous from altered taste or smell function. 413

414 **3.4.2 Subject 45**

Subject 45 reported no symptoms despite becoming an active COVID-19 case
while enrolled. Notably, despite being nominally asymptomatic, she clearly showed
altered smell function that was reflected in both in OdorID performance and orthonasal
intensity ratings, with maximal loss around Day 5. This highlights that some COVID19+ individuals may be unaware of altered smell function, consistent with meta-analysis

420 by Hannum and colleagues [8, 48]. As above, this transient disruption could not be attributed to nasal blockage. Regarding taste ratings, she also exhibited temporal 421 422 dyssynchrony for different qualities. For the Cinnamon jellybeans, she showed a monotonic increase in burn over ~3 weeks, before showing a small drop at the end of 423 the study. Elsewhere, some patients reported an increase in the ability to feel sensations 424 in the mouth (including burning) during recovery from COVID-19 [49], so her temporal 425 pattern may potentially reflect acute hypoalgesia, followed by hyperalgesia, before 426 eventually returning to normal. In any case, her data support the idea that oral 427 chemesthesis can be affected acutely by SARS-CoV-2 infection. 428

429 3.4.3 Subject 62

Like Subject 45, Subject 62 failed to report any symptoms, but unlike the prior 430 431 cases, his orthonasal intensity ratings and OdorID performance remained relatively constant over time, and nasal blockage was generally low. This highlights that while 432 433 many individuals with COVID-19 experience smell loss, some do not (e.g., [8, 48]). Regarding taste, noisy data preclude any strong conclusions, but tentatively, it seems he 434 may have experienced large changes in both sweetness and sourness. That said, there is 435 436 a sharp drop in sour taste intensity and sharp increase in burn intensity on two separate days (Figure 4). We suspect Subject 62 may have simply tasted the wrong sample on 437 these days, as Sour Cherry jellybeans should be sour without any burn. Still, despite 438 these caveats, his panel plots also suggest he experienced acute changes in oral 439 chemesthesis without concomitant smell loss. If true, this would highlight that 440 mechanisms of loss across all three chemosensory modalities are likely to be distinct. 441

442 3.4.3 Subject 63

443 Subject 63 enrolled 2 weeks before becoming a case. This greatly exceeds the expected incubation period (5 to 7 days) [37, 50], so we contacted her via email and she 444 reported a second exposure to a COVID-19+ individual. Thus, we assume she became ill 445 upon her second exposure rather than the initial exposure that caused her to enroll. Her 446 data reveal changes in smell, taste, and chemesthesis. However, the 28-day observation 447 period only captures initial illness without recovery, as she initially enrolled after an 448 exposure that did not cause infection. Consistent with this interpretation, she did not 449 report any symptoms for the first 2 weeks, before reporting many symptoms (sore 450 throat, fever or chills, dry cough, body aches, fatigue, diarrhea, nausea or vomiting, 451

452 headache, and dry cough). Notably, her mean orthonasal ratings began to decline

- somewhat a few days before the estimated day of infection, in the absence of nasal
- 454 blockage. Further, her intensity data suggest she experienced hyposmia, rather than full
- 455 anosmia, so it is not surprising that her OdorID performance remained relatively
- 456 constant across the study period. This suggests rated smell intensity might provide more
- 457 nuanced assessment of smell function versus odor identification (as discussed above).
- 458 Her taste data were somewhat noisy, but it seems sourness may have been more affected
- than sweetness. Tentatively, her plots suggest she lost taste function in a quality specific
- 460 manner, along with partial smell loss and loss of oral chemesthesis, with staggered
- 461 timing of each.




Figure 4: OdorID scores and VAS ratings from four COVID-19 positive individuals. COVID-19 cases (subjects 35, 45, 62, and 63) tended to show transient alterations of smell, taste, and/or chemesthesis during the observation period. To help illustrate uniformity across the study days, solid lines were fit via LOESS regression. A vertical line at Day o was added to highlight the estimated day of infection. Symbols and rows match those used in Figure 3: row 1 is daily number correct, and row 2 is orthonasal intensity of four scratch-n-sniff patches from a ScentCheckPro card, row 3 is ratings of perceived nasal blockage, rows 4-6 are sour, sweet, and burn ratings for Sour Cherry jellybeans with the nose pinched, and row 7 is burn for Cinnamon jellybeans with the nose pinched.

464 3.4 General Discussion

465 By using intensive longitudinal data collected daily for 28 days, we were able to assess COVID-19-associated changes over time. Further, by leveraging enrollment of 466 individuals upon exposure rather than waiting until they were already ill, we were able 467 to create a small case control series that captured both initial loss and recovery. We can 468 draw several conclusions from the results described here. First, number correct on a 469 short odor identification task may potentially miss dysfunction in hyposmic individuals 470 who have clearly depressed perceived intensity, but who still retain enough function to 471 successfully complete an identification task. Longer tests, such as the 40-question 472 University of Pennsylvania Smell Identification Test (Sensonics), may be better at 473 474 differentiating these levels of smell loss, though their greater cost and time-to-complete make them impractical for this type of intensive longitudinal study. Second, we find 475 476 smell loss appears maximal around Day 5, but this varies somewhat across participants. Third, COVID-19 related chemosensory dysfunction can manifest as reduced oral 477 chemesthesis, reduced taste, and/or reduced orthonasal smell with little to no nasal 478 blockage, with temporally staggered onset and time course. Collectively, these results, 479 480 although limited in scope, extend prior work by providing direct assessment of multiple sensory modalities repeatedly over time using stable, commercially-available products 481 as stimuli. 482

A strength of this study involved the use of commercial stimuli like jellybeans to 483 collect ratings while the nose was blocked with nose clips. First, because of their glazed 484 485 candy shell, jellybeans have little to no orthonasal scent and the odorant is only released from the food matrix upon chewing. For our purpose, this gave us a convenience way to 486 487 deliver consistent shelf stable stimuli safely during a pandemic. All jellybeans of the same flavor came from the same lot; given routine quality control measures in 488 commercial manufacturing, we are confident participants received consistent stimuli 489 even if we do not know the exact formulation of the jellybeans. Second, our use of 490 similarly colored jellybeans with different flavors minimizes potential biases 491 participants may have from prior experience or knowledge with other foods (e.g., this is 492 493 a lemon, and I know lemons tend to be sour [51]). When this lack of expectation is coupled with the use of nose clips, we believe the data shown here reflect true 494 differences in taste and chemesthesis and not merely they result of a flavor taste 495

496 confusion. Other studies have also reported loss in function when using taste stimuli497 that do not have an olfactory component [52].

498 Currently, there is disagreement regarding whether different types of taste cells 499 are differentially affected by SARS-CoV-2 infection. Indeed, several studies have showed quality-specific differences (i.e., [27, 43, 53-56]), while others have not (i.e., [18, 40-42, 500 57-61]). Here, sourness and sweetness from consistent stimuli were lost and recovered 501 at similar rates for some participants, but this was not uniformly true. This implies 502 specific taste qualities may recover at different rates, although additional work is needed 503 to confirm this. Also, our data indicate taste qualities may be differentially affected, 504 505 consistent with other reports [19, 62]. While the specific mechanisms underlying taste dysfunction with SARS-CoV-2 infection remain unclear, several mechanisms have be 506 507 proposed. For example, ACE2 could allow for the infection of Type 2 (sweet, bitter and umami) taste receptor cells by SARS-CoV-2. Saliva could affect gustation as salivary 508 509 glands express high levels of ACE2 and TMPRSS2. SARS-CoV-2 may even affect the central nervous system, as the virus has been detected in the cerebrospinal fluid [63-67]. 510

Anecdotal reports and preliminary psychophysics suggest loss of chemesthesis 511 512 with SARS-CoV-2 infection is real [10, 23, 30, 68]. We extend prior reports here by showing oral chemesthesis, not just nasal chemesthesis, may be altered by COVID-19. 513 This effect appears to be highly transitory, which could cause underreporting, especially 514 when assessment occurs multiple days after illness has started. Definitionally, 515 chemesthesis includes both thermal and tactile percepts like warming, cooling, and 516 buzzing, and these sensations occur via distinct and specialized receptors. Even if 517 518 focusing solely on burn, multiple receptors like TRPV1 and TRPA1 are involved. Despite 519 multiple advantages of commercial stimuli (high consistency, low cost, shelf stability, etc.), use of commercial jellybeans here limits interpretation somewhat. That is, 520 cinnamon flavored candies presumably contain cinnamaldehyde, a well-known TRPA1 521 agonist [69, 70]. However, we cannot rule out whether they contain capsaicin (or 522 another TRPV1 agonist), as food labeling laws in the United States allow manufacturers 523 to declare such ingredients as natural or artificial flavors on the package without being 524 525 more specific, so we cannot make strong inferences about which specific chemesthetic mechanisms might be affected by SARS-CoV-2 infection. Nonetheless, present data 526 extend prior work by clearly showing oral burn can be transiently affected by COVID-19. 527

528 4. Limitations and Conclusions

529 Our data suggest intensive cohort study designs are imperative for understanding and tracking symptoms of COVID-19 patients. Through intensive daily ratings we were 530 able to examine and follow participants from initial exposure to catch symptoms as the 531 emerged, allowing for the visualization of symptom onset, not just recovery. Thus, a 532 strength of this study is the nature of the cohort examined, and it exemplifies a need for 533 more cohort studies to catch patients before and during the most infectious period of 534 their illness. A few limitations should be briefly noted. First, all sensory testing in this 535 study was performed remotely at home, due to pandemic related safety restrictions 536 meant to protect both participants and our research team. Because participants made 537 538 daily ratings at their leisure without direct supervision, we cannot obtain the same level 539 of stimulus control we would have with an in-person lab-based study. Also, while all 540 study materials were clearly labeled, we cannot preclude whether participants may have occasionally chosen the incorrect blinding codes on some days or that our staff might 541 have mislabeled these samples. Further, we should note the commercial ScentCheckPro 542 scratch-n-sniff cards used here were not validated as a clinical smell test; also, they were 543 originally designed as an odor identification task, rather than a smell intensity task, so 544 we cannot assume all stimulus concentrations were precisely matched for intensity. This 545 concern is partially offset however by the randomization of odorants on any given card, 546 and the use of daily means. Finally, we fully acknowledge this study had a very small 547 number of participants (albeit with many data points per participant), so present 548 549 findings should be taken as tentative until confirmed. Attempts to generalize the 550 incidence or prevalence of distinct types of loss or dysfunction should not be made from 551 this small case-control series. Despite these limitations, this dataset is highly unique in that it captures changes very early in COVID-19 illness with intensive daily sampling. 552

Here, we extend current knowledge by showing oral chemesthesis, taste, and/or orthonasal smell function can each be acutely affected by COVID-19. Further, we find such disruption may be dyssynchronous for the different chemical senses, with differing rates of loss and recovery across modalities and individuals. Also, odor intensity ratings revealed potentially hyposmic individuals who might be missed if smell function is only assessed via odor identification scores. Finally, disrupted chemosensation, especially for

- chemesthesis, appears to be highly transient, suggesting studies that collect a single
- snapshot in time, often retrospectively, may underestimate the true prevalence of loss.
- 561

562 **5. Acknowledgements**

The authors wish to thank our participants for their time and critical contribution to thiswork.

565

566 6. Funding / COI disclosure


- 567 EMW, SM, JEH and RCG each receive partial salary support from a competitive grant
- 568 [1U01DC019573] from the National Institutes of Deafness and Communications
- 569 Disorders (NIDCD); JEH also receives salary support from the United States
- 570 Department of Agriculture (USDA) via the National Institute of Food and Agriculture
- 571 (NIFA) Hatch Act Appropriations [Project PEN04708 and Accession # 1019852]. Drs.
- 572 Munger, Hayes, and Gerkin each hold equity in Redolynt, LLC, which they co-founded
- 573 in 2021. This financial interest has been reviewed by the Individual Conflict of Interest
- 574 Committee at each of their respective universities and is being actively being managed
- 575 by each university. None of the other authors have any conflicts to disclose.

576

578 Supplemental Materials

579


- 580 Supplemental Figure 1
- 581



Raw daily odor identification scores from the ScentCheckPro cards over time for the
COVID-19 cases (n=15) who entered the study on or before day 10 of their infection.

585 Supplemental Figure 2

586



587

Raw daily odor identification scores from the ScentCheckPro cards over time for the 15controls.

591 Supplemental narrative and discussion of symptoms for the 4 cases

592 Subject 35

593 Subject 35 became a case during the study, enabling visualization of the falling and rising phases of her responses (see Figure 4). Her symptoms included cough, runny 594 nose/congestion, sore throat, and headache. Regarding orthonasal scratch-n-sniff 595 intensity ratings, daily means decreased through day 15 before recovering. OdorID 596 scores showed a similar pattern, but data were noisier given the learning effect 597 described above. Together, this suggests her orthonasal olfaction was transiently 598 affected during active COVID-19 infection, as expected (e.g., [19, 71, 72]). Notably, she 599 600 showed impaired smell even after nasal blockage resolved around Day 8, and her maximal smell loss and maximal nasal blockage were dyssynchronous. This is consistent 601 602 with other reports showing COVID-19 smell loss is not associated with nasal blockage [4-7, 10], presumably because COVID-19-associated loss arises from ACE2 receptor-603 604 mediated disruption of the olfactory epithelium, and not the conductive losses seen with the common cold. 605

Her sourness ratings from the Sour Cherry jellybean declined until ~Day 15. 606 607 when ratings began to increase, while sweetness declined until ~Day 6, before beginning to recover. The decline and subsequent rise of sweet and sour taste likely signifies 608 normal recovery, although Figure 4 also shows dyssynchronous recovery of these tastes 609 (i.e., sweetness did not recover as swiftly as sourness). These data indicate sweet and 610 sour taste are each transiently affected with an active COVID-19 infection, and this was 611 not merely a taste/flavor semantic confusion, as ratings were obtained while wearing 612 613 nose clips. Subject 35 also showed large changes in burn from the Cinnamon jellybeans, 614 suggesting oral chemesthesis is affected by COVID-19. The lack of burn from the Sour Cherry jellybeans serves as a negative control, indicating she was successful in 615 discriminating between burn from a Cinnamon jellybean and a lack of burn from a Sour 616 Cherry jellybean (a pattern also seen in the three other cases shown in Figure 4). These 617 data indicate perception of oral burn can be affected by an active COVID-19 infection 618 dyssynchronously from taste or smell. While patient anecdotes (including social media 619 posts) have previously suggested nasal and/or oral chemesthesis may be affected by 620 SARS-CoV-2 infection [39, 49, 73], the daily assessment and prospective design used 621 here provide quantitative evidence of altered oral chemesthesis with COVID-19. 622

623 Subject 45

Subject 45 converted from being a close contact to an active COVID-19 case 624 625 during the study, but unlike Subject 35, Subject 45 never reported any symptoms during her infection. Yet. despite being nominally asymptomatic, she still showed a clear drop 626 in both OdorID performance and ratings of orthonasal intensity around Day 5 (with a 627 bigger effect size for intensity). This highlights that some individuals infected with 628 SARS-CoV-2 may be unaware of the impact on their sensory abilities, consistent with 629 recent meta-analysis by Hannum and colleagues [8, 48]. Nor was this transient 630 disruption in smell due to nasal blockage (as reported elsewhere [4-7, 10]). As her 631 infection progressed, sourness from the Sour Cherry jellybean was variable, and 632 sweetness from this jellybean steadily declined over the course of infection, again 633 634 indicative of temporal dyssynchrony for different taste qualities. In contrast to burn rating from the Sour Cherry jellybean (which staved near o across the study period, as 635 636 expected), burn from the Cinnamon jellybean steadily increased in a monotonic fashion until a small drop was observed at the end of the study. Taken together with data from 637 Subject 35, this indicates suggests oral chemesthesis is altered by active SARS-CoV-2 638 639 infection. Another study noted that during recovery from COVID-19, some patients report an increase in the ability to feel sensations in the mouth, including burning [49]. 640

641 Subject 62

Subject 62's infection began 1 day before enrollment. Like Subject 45, he failed to 642 self-report any symptoms, but unlike Subjects 35 and 45, his orthonasal intensity 643 ratings and OdorID performance remained relatively constant throughout the study 644 645 period, and his nasal blockage was generally low - while many individuals experience 646 smell loss with COVID-19, some do not (e.g., [8, 48]). Regarding taste, noisy data make 647 it hard to draw any strong conclusions, but it still seems he may have experienced substantial changes in sour and sweet taste. Regarding burn, he rated the burn from 648 Sour Cherry jellybeans near zero for the entire study, suggesting he successfully 649 distinguished burn from the Cinnamon jellybean from the lack of burn from the Sour 650 Cherry jellybean (like the other cases). Two other values merit comment: in the 1st and 651 3rd week of testing, a sharp drop in sour taste intensity and sharp increase in burn 652 intensity can be seen on two separate days; we suspect he may have misread the 653 654 blinding codes, tasting the wrong sample on these days, as Sour Cherry jellybeans

should be sour without any burn. Still, despite noise in his ratings, his panel plots for

burn suggest he experienced transient changes in oral chemesthesis. If this case did in

- 657 fact experience altered burn and altered taste without concomitant smell loss, this
- would emphasize that mechanisms of loss across all three modalities are distinct, with
- the caveat that the noise in these data should temper any strong inferences.

660 Subject 63

Subject 63 enrolled 2 weeks days before becoming a case. Because this greatly 661 exceeds the expected incubation period of 5 to 7 days [37, 50], our study team contacted 662 her via email. At that point, she reported a second exposure to an individual with 663 COVID-19 - we assume this second exposure was the source of the infection 664 documented here. Her data reveals changes in smell, taste, and chemesthesis as she 665 transitioned from being a close contact to being a case, but the observation period only 666 captures her initial illness without any recovery as she had enrolled after her first 667 668 exposure that did not cause an infection. Consistent with this interpretation, she did not report any symptoms for the first 2 weeks, but then began reporting many symptoms 669 (sore throat, fever or chills, dry cough, body aches, fatigue, diarrhea, nausea or 670 671 vomiting, headache, and dry cough). Notably, her mean orthonasal ratings began to decline somewhat a few days before the estimated day of infection, but she indicated 672 little to no nasal blockage, as expected [4-7, 10]. Also, her intensity ratings suggest she 673 experienced hyposmia, rather than full anosmia, so it is unsurprising that her OdorID 674 675 performance remained relatively constant across the study period, with some evidence of a slight learning effect near the beginning of the study. As discussed previously, this 676 677 suggests rated smell intensity might provide more nuanced assessment of smell function 678 versus odor identification. We have no obvious explanation for her unexpectedly low 679 sourness ratings on the first two days of the study. Still, if her peak ratings during this initial (uninfected) period are tentatively treated as a baseline, we see a subsequent 680 decline in sourness around the time her other symptoms appeared. For the rest of the 681 study, her sour ratings remained relatively depressed, at least relative to the maximal 682 values she reported pre-infection. In contrast, sweetness, while noisy, appeared more 683 constant across the entire study. Tentatively, these plots suggest Subject 63 lost some 684 taste function in a quality specific manner, as well as partial smell loss and loss of oral 685 chemesthesis, with staggered timing of each, during her infection. 686

687		
688		References
689		
690	1.	Morens, D.M., J.K. Taubenberger, and A.S. Fauci, A centenary tale of two pandemics: the
691		1918 influenza pandemic and COVID-19, part I. American journal of public health, 2021.
692		111 (6): p. 1086-1094.
693	2.	da Costa, V.G., M.V. Saivish, D.E.R. Santos, R.F. de Lima Silva, and M.L. Moreli,
694		Comparative epidemiology between the 2009 H1N1 influenza and COVID-19 pandemics.
695		Journal of infection and public health, 2020. 13 (12): p. 1797-1804.
696	3.	WHO. World Health Organization (COVID-19) Dashboard. 2022; Available from:
697	-	https://covid19.who.int.
698	4.	Passarelli, P.C., M.A. Lopez, G.M. Bonaviri, F. Garcia-Godoy, and A. D'Addona, <i>Taste and</i>
699 700		smell as chemosensory dysfunctions in COVID-19 infection. Am J Dent, 2020. 33 (3): p.
700 701	5.	135-137. Bellogring R. K.W. Cooper A. Di Dizio, R.V. Jacoph S. Rhutani, and V. Darma
701	5.	Pellegrino, R., K.W. Cooper, A. Di Pizio, P.V. Joseph, S. Bhutani, and V. Parma, Coronaviruses and the chemical senses: past, present, and future. Chemical senses,
702		2020. 45 (6): p. 415-422.
704	6.	Printza, A., M. Katotomichelakis, K. Valsamidis, S. Metallidis, P. Panagopoulos, M.
705	0.	Panopoulou, et al., Smell and Taste Loss Recovery Time in COVID-19 Patients and
706		Disease Severity. Journal of Clinical Medicine, 2021. 10 (5): p. 966.
707	7.	Menni, C., A.M. Valdes, M.B. Freidin, C.H. Sudre, L.H. Nguyen, D.A. Drew, et al., <i>Real-</i>
708		time tracking of self-reported symptoms to predict potential COVID-19. Nature medicine,
709		2020: p. 1-4.
710	8.	Hannum, M.E., V.A. Ramirez, S.J. Lipson, R.D. Herriman, A.K. Toskala, C. Lin, et al.,
711		Objective sensory testing methods reveal a higher prevalence of olfactory loss in COVID-
712		19–positive patients compared to subjective methods: A systematic review and meta-
713	_	analysis. medRxiv, 2020.
714	9.	Gerkin, R.C., K. Ohla, M.G. Veldhuizen, P.V. Joseph, C.E. Kelly, A.J. Bakke, et al., <i>Recent</i>
715		smell loss is the best predictor of COVID-19 among individuals with recent respiratory
716	10	symptoms. Chemical senses, 2021. 46 .
717 718	10.	Parma, V., K. Ohla, M.G. Veldhuizen, M.Y. Niv, C.E. Kelly, A.J. Bakke, et al., <i>More than smell—COVID-19 is associated with severe impairment of smell, taste, and chemesthesis.</i>
718		Chemical Senses, 2020. 45 (7): p. 609-622.
720	11.	Karni, N., H. Klein, K. Asseo, Y. Benjamini, S. Israel, M. Nimri, et al., <i>Self-rated smell</i>
721	±±.	ability enables highly specific predictors of COVID-19 status: a case control study in
722		<i>Israel.</i> medRxiv, 2020: p. 2020.07.30.20164327.
723	12.	Huart, C., C. Philpott, I. Konstantinidis, A. Altundag, E.M.C. Trecca, M. Cassano, et al.,
724		Comparison of COVID-19 and common cold chemosensory dysfunction. Rhinology, 2020.
725	13.	Ohla, K., M.G. Veldhuizen, T. Green, M.E. Hannum, A.J. Bakke, S. Moein, et al.,
726		Increasing incidence of parosmia and phantosmia in patients recovering from COVID-19
727		smell loss. medRxiv, 2021.
728	14.	Green, B.G., Introduction: what is chemesthesis? Chemesthesis: Chemical touch in food
729		and eating, 2016: p. 1-7.

730	15.	Borsetto, D., C. Hopkins, V. Philips, R. Obholzer, G. Tirelli, J. Polesel, et al., Self-reported
731		alteration of sense of smell or taste in patients with COVID-19: a systematic review and
732		<i>meta-analysis on 3563 patients.</i> Rhinology, 2020. 58 (5): p. 430-436.
733	16.	Dawson, P., E.M. Rabold, R.L. Laws, E.E. Conners, R. Gharpure, S. Yin, et al., Loss of taste
734		and smell as distinguishing symptoms of COVID-19. Clinical Infectious Diseases, 2020.
735	17.	Printza, A. and J. Constantinidis, The role of self-reported smell and taste disorders in
736		suspected COVID-19. European Archives of Oto-Rhino-Laryngology, 2020. 277: p. 2625-
737		2630.
738	18.	Mazzatenta, A., G. Neri, D. D'Ardes, C. De Luca, S. Marinari, E. Porreca, et al., Smell and
739		taste in severe CoViD-19: self-reported vs. testing. Frontiers in Medicine, 2020. 7.
740	19.	Konstantinidis, I., A. Delides, E. Tsakiropoulou, P. Maragoudakis, S. Sapounas, and S.
741		Tsiodras, Short-Term Follow-Up of Self-Isolated COVID-19 Patients with Smell and Taste
742		Dysfunction in Greece: Two Phenotypes of Recovery. ORL, 2020. 82 (6): p. 295-303.
743	20.	Callejon-Leblic, M.A., R. Moreno-Luna, A. Del Cuvillo, I.M. Reyes-Tejero, M.A. Garcia-
744	20.	Villaran, M. Santos-Peña, et al., Loss of Smell and Taste Can Accurately Predict COVID-19
745		Infection: A Machine-Learning Approach. Journal of clinical medicine, 2021. 10 (4): p.
746		570.
740	21.	Liou, JM., MJ. Chen, TC. Hong, and MS. Wu, <i>Alteration of taste or smell as a</i>
747	21.	predictor of COVID-19. Gut, 2021. 70 (4): p. 806-807.
	22	
749	22.	Hayes, J.E.P., Valentina. COVID-19, smell and taste – how is COVID-19 different from
750		other respiratory diseases? 2020; Available from: <u>https://theconversation.com/covid-</u>
751	22	<u>19-smell-and-taste-how-is-covid-19-different-from-other-respiratory-diseases-139543</u> .
752	23.	Ferreli, F., M. Di Bari, F. Gaino, A. Albanese, L.S. Politi, G. Spriano, et al. <i>Trigeminal</i>
753		features in COVID-19 patients with smell impairment. in International Forum of Allergy &
754		Rhinology. 2021: Wiley-Blackwell.
755	24.	Iravani, B., A. Arshamian, A. Ravia, E. Mishor, K. Snitz, S. Shushan, et al., <i>Relationship</i>
756		between odor intensity estimates and COVID-19 prevalence prediction in a Swedish
757		population. Chemical senses, 2020. 45 (6): p. 449-456.
758	25.	Paderno, A., D. Mattavelli, V. Rampinelli, A. Grammatica, E. Raffetti, M. Tomasoni, et al.,
759		Olfactory and gustatory outcomes in COVID-19: A prospective evaluation in
760		nonhospitalized subjects. Otolaryngology–Head and Neck Surgery, 2020. 163(6): p.
761		1144-1149.
762	26.	Gerkin, R.C., K. Ohla, M.G. Veldhuizen, P.V. Joseph, C.E. Kelly, A.J. Bakke, et al., The best
763		COVID-19 predictor is recent smell loss: a cross-sectional study. medRxiv, 2020.
764	27.	Niklassen, A.S., J. Draf, C. Huart, C. Hintschich, S. Bocksberger, E.M.C. Trecca, et al.,
765		COVID-19: Recovery from chemosensory dysfunction. A multicentre study on smell and
766		<i>taste.</i> The Laryngoscope, 2021. 131 (5): p. 1095-1100.
767	28.	Blomberg, B., K.GI. Mohn, K.A. Brokstad, F. Zhou, D.W. Linchausen, BA. Hansen, et al.,
768		Long COVID in a prospective cohort of home-isolated patients. Nature Medicine, 2021: p.
769		1-7.
770	29.	Klein, H., K. Asseo, N. Karni, Y. Benjamini, R. Nir-Paz, M. Muszkat, et al., Onset, duration
771		and unresolved symptoms, including smell and taste changes, in mild COVID-19
772		<i>infection: a cohort study in Israeli patients.</i> Clinical Microbiology and Infection, 2021.
		,,,,

773	30.	Otte, M.S., ML. Bork, P.H. Zimmermann, J.P. Klußmann, and JC. Lüers, Patients with
774		COVID-19-associated olfactory impairment also show impaired trigeminal function. Auris
775		Nasus Larynx, 2021.
776	31.	Boscolo-Rizzo, P., F. Guida, J. Polesel, A.V. Marcuzzo, P. Antonucci, V. Capriotti, et al.,
777		Self-reported smell and taste recovery in coronavirus disease 2019 patients: a one-year
778		prospective study. European Archives of Oto-Rhino-Laryngology, 2022. 279(1): p. 515-
779		520.
780	32.	Harris, P.A., R. Taylor, R. Thielke, J. Payne, N. Gonzalez, and J.G. Conde, Research
781		electronic data capture (REDCap)—a metadata-driven methodology and workflow
782		process for providing translational research informatics support. Journal of biomedical
783		informatics, 2009. 42 (2): p. 377-381.
784	33.	Harris, P.A., R. Taylor, B.L. Minor, V. Elliott, M. Fernandez, L. O'Neal, et al., The REDCap
785		consortium: Building an international community of software platform partners. Journal
786		of biomedical informatics, 2019. 95 : p. 103208.
787	34.	Clark, C.C. and H.T. Lawless, Limiting response alternatives in time-intensity scaling: an
788		<i>examination of the halo-dumping effect.</i> Chemical senses, 1994. 19 (6): p. 583-594.
789	35.	Wang, J., An intuitive tutorial to Gaussian processes regression. arXiv preprint
790		arXiv:2009.10862, 2020.
791	36.	Klein, H., K. Asseo, N. Karni, Y. Benjamini, R. Nir-Paz, M. Muszkat, et al., Onset, duration
792		and unresolved symptoms, including smell and taste changes, in mild COVID-19
793		infection: a cohort study in Israeli patients. Clinical Microbiology and Infection, 2021.
794		27 (5): p. 769-774.
795	37.	Lauer, S.A., K.H. Grantz, Q. Bi, F.K. Jones, Q. Zheng, H.R. Meredith, et al., The Incubation
796		Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases:
797		Estimation and Application. Annals of Internal Medicine, 2020. 172(9): p. 577-582.
798	38.	Printza, A. and J. Constantinidis, The role of self-reported smell and taste disorders in
799		suspected COVID-19. European Archives of Oto-Rhino-Laryngology, 2020. 277(9): p.
800		2625-2630.
801	39.	Cecchetto, C., A. Di Pizio, F. Genovese, O. Calcinoni, A. Macchi, A. Dunkel, et al.,
802		Assessing the extent and timing of chemosensory impairments during COVID-19
803		<i>pandemic.</i> Scientific Reports, 2021. 11 (1): p. 1-12.
804	40.	Vaira, L.A., J.R. Lechien, G. Salzano, F.A. Salzano, F. Maglitto, S. Saussez, et al., Gustatory
805		Dysfunction: A Highly Specific and Smell-Independent Symptom of COVID-19. Indian
806		Journal of Otolaryngology and Head & Neck Surgery, 2020: p. 1-3.
807	41.	Vaira, L.A., C. Hopkins, G. Salzano, M. Petrocelli, A. Melis, M. Cucurullo, et al., Olfactory
808		and gustatory function impairment in COVID-19 patients: Italian objective multicenter-
809		<i>study.</i> Head & neck, 2020. 42 (7): p. 1560-1569.
810	42.	Hintschich, C.A., J.J. Wenzel, T. Hummel, M.K. Hankir, T. Kühnel, V. Vielsmeier, et al.
811		Psychophysical tests reveal impaired olfaction but preserved gustation in COVID-19
812		patients. in International forum of allergy & rhinology. 2020: Wiley-Blackwell.
813	43.	Singer-Cornelius, T., J. Cornelius, M. Oberle, F.U. Metternich, and S.J. Brockmeier,
814		Objective gustatory and olfactory dysfunction in COVID-19 patients: a prospective cross-
815		sectional study. European Archives of Oto-Rhino-Laryngology, 2021: p. 1-8.

816 44. Lyu, C., D. Schijvens, J.E. Hayes, and M. Stieger, <i>Capsaicin burn increases</i>	
817 <i>discrimination thresholds independently of chronic chili intake.</i> Food Rese	earch
818 International, 2021. 149 : p. 110702.	
819 45. Nolden, A.A. and J.E. Hayes, <i>Perceptual and affective responses to sample</i>	•
820 <i>differ by reported intake.</i> Food quality and preference, 2017. 55 : p. 26-34	
821 46. Lawless, H., Oral chemical irritation: Psychophysical properties. Chemical	Senses, 1984.
822 9 (2): p. 143-155.	
823 47. Lawless, H., P. Rozin, and J. Shenker, <i>Effects of oral capsaicin on gustator</i>	
824 irritant sensations and flavor identification in humans who regularly or re	arely consume
825 <i>chili pepper.</i> Chemical senses, 1985. 10 (4): p. 579-589.	
826 48. Hannum, M.E., R.J. Koch, V.A. Ramirez, S.S. Marks, A.K. Toskala, R.D. Her	
827 Taste loss as a distinct symptom of COVID-19: A systematic review and m	neta-analysis.
828 medRxiv, 2021: p. 2021.10.09.21264771.	
829 49. Al-Rawi, N.H., A.R. Sammouda, E.A. AlRahin, F.A. Al Ali, G.S. Al Arayedh, H	
830 Daryanavard, et al., <i>Prevalence of Anosmia or Ageusia in COVID-19 Patie</i>	nts Among UAE
831 <i>Population.</i> International Dental Journal, 2021.	
832 50. Cimolai, N., In pursuit of the right tail for the COVID-19 incubation period	. Public Health,
833 2021. 194 : p. 149-155.	
834 51. Hintschich, C.A., M.Y. Niv, and T. Hummel. <i>The taste of the pandemic—co</i>	
835 review on the current state of research on gustation in coronavirus diseas	se 2019 (COVID-
836 <i>19</i>). in <i>International Forum of Allergy & Rhinology</i> : Wiley Online Library.	
837 52. Nguyen, H., J. Albayay, R. Höchenberger, S. Bhutani, S. Boesveldt, N.A. Bu	
838 Covid-19 affects taste independently of smell: results from a combined ch	•
839 home test and online survey from a global cohort (N=10,953). medRxiv, 2	2023: p.
840 2023.01.16.23284630.	
841 53. Salcan, İ., F. Karakeçili, S. Salcan, E. Ünver, S. Akyüz, E. Seçkin, et al., <i>Is ta</i>	
842 <i>impairment irreversible in COVID-19 patients?</i> European Archives of Oto-	-Rhino-
843 Laryngology, 2021. 278 (2): p. 411-415.	
844 54. Altin, F., C. Cingi, T. Uzun, and C. Bal, Olfactory and gustatory abnormalit	
845 <i>cases.</i> European Archives of Oto-Rhino-Laryngology, 2020. 277 (10): p. 27	
846 55. Bidkar, V., M. Mishra, K. Selvaraj, P. Joshi, B. Shrikrishna, S. Dabhekar, et	-
847 Olfactory and Gustatory Dysfunctions among Quarantine COVID-19 Susp	ects. Indian
848Journal of Otolaryngology and Head & Neck Surgery, 2020: p. 1-6.	
849 56. Adamczyk, K., M. Herman, J. Fraczek, R. Piec, B. Szykula-Piec, A. Zaczynsk	
850 Sensitivity and specifity of prediction models based on gustatory disorder	rs in diagnosing
851 <i>COVID-19 patients: a case-control study.</i> medRxiv, 2020.	
852 57. Vaira, L.A., G. Deiana, A.G. Fois, P. Pirina, G. Madeddu, A. De Vito, et al.,	
853 evaluation of anosmia and ageusia in COVID-19 patients: single-center ex	xperience on 72
854 <i>cases.</i> Head & neck, 2020. 42 (6): p. 1252-1258.	
855 58. Vaira, L.A., C. Hopkins, M. Petrocelli, J. Lechien, C. Chiesa-Estomba, G. Sa	
856 Smell and taste recovery in coronavirus disease 2019 patients: a 60-day of	•
857 prospective study. The Journal of Laryngology & Otology, 2020. 134 (8): p	
858 59. Vaira, L.A., C. Hopkins, M. Petrocelli, J.R. Lechien, D. Soma, F. Giovanditto	
859 olfactory and gustatory psychophysical scores have prognostic value in C	OVID-19

860		patients? A prospective study of 106 patients. Journal of Otolaryngology-Head & Neck
861		Surgery, 2020. 49 (1): p. 1-10.
862	60.	Vaira, L.A., G. Salzano, M. Petrocelli, G. Deiana, F.A. Salzano, and G. De Riu, <i>Validation of</i>
863		a self-administered olfactory and gustatory test for the remotely evaluation of COVID-19
864		<i>patients in home quarantine.</i> Head & neck, 2020. 42 (7): p. 1570-1576.
865	61.	Petrocelli, M., S. Cutrupi, G. Salzano, F. Maglitto, F. Salzano, J. Lechien, et al., <i>Six-month</i>
866		smell and taste recovery rates in coronavirus disease 2019 patients: a prospective
867		psychophysical study. The Journal of Laryngology & Otology, 2021: p. 1-6.
868	62.	Burges Watson, D.L., M. Campbell, C. Hopkins, B. Smith, C. Kelly, and V. Deary, Altered
869		smell and taste: Anosmia, parosmia and the impact of long Covid-19. PloS one, 2021.
870		16 (9): p. e0256998.
871	63.	Doyle, M.E., A. Appleton, QR. Liu, Q. Yao, C.H. Mazucanti, and J.M. Egan, <i>Human Taste</i>
872		Cells Express ACE2: a Portal for SARS-CoV-2 Infection. bioRxiv, 2021.
873	64.	Hoffmann, M., H. Kleine-Weber, S. Schroeder, N. Krüger, T. Herrler, S. Erichsen, et al.,
874		SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically
875		proven protease inhibitor. cell, 2020. 181 (2): p. 271-280. e8.
876	65.	Xu, H., L. Zhong, J. Deng, J. Peng, H. Dan, X. Zeng, et al., <i>High expression of ACE2 receptor</i>
877		of 2019-nCoV on the epithelial cells of oral mucosa. International journal of oral science,
878		2020. 12 (1): p. 1-5.
879	66.	Lewis, A., J. Frontera, D.G. Placantonakis, J. Lighter, S. Galetta, L. Balcer, et al.,
880		Cerebrospinal fluid in COVID-19: A systematic review of the literature. Journal of the
881		neurological sciences, 2021: p. 117316.
882	67.	Matschke, J., M. Lütgehetmann, C. Hagel, J.P. Sperhake, A.S. Schröder, C. Edler, et al.,
883		Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. The
884		Lancet Neurology, 2020. 19 (11): p. 919-929.
885	68.	Hayes, J.E., & Parma, V. COVID-19, smell and taste – how is COVID-19 different from
886		other respiratory diseases? . 2020.
887	69.	Alpizar, Y.A., T. Voets, and K. Talavera, Molecular mechanisms underlying the role of TRP
888		channels in chemesthesis. Chemesthesis: Chemical Touch in Food and Eating, 2016: p.
889		48.
890	70.	Bandell, M., G.M. Story, S.W. Hwang, V. Viswanath, S.R. Eid, M.J. Petrus, et al., <i>Noxious</i>
891		cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron,
892		2004. 41 (6): p. 849-857.
893	71.	Chiesa-Estomba, C.M., J.R. Lechien, T. Radulesco, J. Michel, L.J. Sowerby, C. Hopkins, et
894		al., Patterns of smell recovery in 751 patients affected by the COVID-19 outbreak.
895		European journal of neurology, 2020. 27 (11): p. 2318-2321.
896	72.	Reiter, E.R., D.H. Coelho, Z.A. Kons, and R.M. Costanzo, Subjective smell and taste
897		changes during the COVID-19 pandemic: Short term recovery. American Journal of
898		Otolaryngology, 2020. 41 (6): p. 102639.
899	73.	Chaaban, N., A.T.Z.B. Høier, and B.V. Andersen, A Detailed Characterisation of Appetite,
900		Sensory Perceptional, and Eating-Behavioural Effects of COVID-19: Self-Reports from the
901		Acute and Post-Acute Phase of Disease. Foods, 2021. 10 (4): p. 892.
902		